Cargando…
Cutaneous Leukocytoclastic Vasculitis Induced by Apixaban and/or Rivaroxaban With Seronegative Anti-Neutrophil Cytoplasmic Antibody (ANCA) Titers: A Case Report and Literature Review
A 45-year-old man presented with a diffuse petechial rash and a non-blanching palpable purpura, mainly on his lower extremities, some of which had coalesced, blistered, and ulcerated. The patient had a history of hypercoagulability and was chronically on anticoagulant medication. The rash appeared a...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540658/ https://www.ncbi.nlm.nih.gov/pubmed/37779775 http://dx.doi.org/10.7759/cureus.44376 |
_version_ | 1785113756776267776 |
---|---|
author | El-Sabbagh, Mohamad Rifai, Sarah Sabah, Zainalabedeen M Tarakji, Adam M Rifai, Ahmad O Dahan, Sally Denig, Kristin M |
author_facet | El-Sabbagh, Mohamad Rifai, Sarah Sabah, Zainalabedeen M Tarakji, Adam M Rifai, Ahmad O Dahan, Sally Denig, Kristin M |
author_sort | El-Sabbagh, Mohamad |
collection | PubMed |
description | A 45-year-old man presented with a diffuse petechial rash and a non-blanching palpable purpura, mainly on his lower extremities, some of which had coalesced, blistered, and ulcerated. The patient had a history of hypercoagulability and was chronically on anticoagulant medication. The rash appeared a week after starting apixaban 5 mg twice daily by mouth. Prior to that, he was receiving rivaroxaban. The rash was biopsied, which demonstrated cutaneous leukocytoclastic vasculitis (LCV). Serum anti-neutrophil cytoplasmic antibody (ANCA) titers were negative. Complement levels of C3, C4, and CH50 were normal. Hepatitis C antibodies were negative. HIV antibodies were non-reactive. Titers for Lyme disease and Rocky Mountain spotted fever were nonreactive. It is unusual for a drug to induce cutaneous LCV with negative ANCA titers. Although rare, it usually requires aggressive therapy. Our case resolved after the discontinuation of apixaban and rivaroxaban and the initiation of warfarin for hypercoagulability in conjunction with a short course of steroids. As the use of apixaban and rivaroxaban increases, we may see a consequent increase in cutaneous LCV that is specifically ANCA-negative. |
format | Online Article Text |
id | pubmed-10540658 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-105406582023-09-30 Cutaneous Leukocytoclastic Vasculitis Induced by Apixaban and/or Rivaroxaban With Seronegative Anti-Neutrophil Cytoplasmic Antibody (ANCA) Titers: A Case Report and Literature Review El-Sabbagh, Mohamad Rifai, Sarah Sabah, Zainalabedeen M Tarakji, Adam M Rifai, Ahmad O Dahan, Sally Denig, Kristin M Cureus Allergy/Immunology A 45-year-old man presented with a diffuse petechial rash and a non-blanching palpable purpura, mainly on his lower extremities, some of which had coalesced, blistered, and ulcerated. The patient had a history of hypercoagulability and was chronically on anticoagulant medication. The rash appeared a week after starting apixaban 5 mg twice daily by mouth. Prior to that, he was receiving rivaroxaban. The rash was biopsied, which demonstrated cutaneous leukocytoclastic vasculitis (LCV). Serum anti-neutrophil cytoplasmic antibody (ANCA) titers were negative. Complement levels of C3, C4, and CH50 were normal. Hepatitis C antibodies were negative. HIV antibodies were non-reactive. Titers for Lyme disease and Rocky Mountain spotted fever were nonreactive. It is unusual for a drug to induce cutaneous LCV with negative ANCA titers. Although rare, it usually requires aggressive therapy. Our case resolved after the discontinuation of apixaban and rivaroxaban and the initiation of warfarin for hypercoagulability in conjunction with a short course of steroids. As the use of apixaban and rivaroxaban increases, we may see a consequent increase in cutaneous LCV that is specifically ANCA-negative. Cureus 2023-08-30 /pmc/articles/PMC10540658/ /pubmed/37779775 http://dx.doi.org/10.7759/cureus.44376 Text en Copyright © 2023, El-Sabbagh et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Allergy/Immunology El-Sabbagh, Mohamad Rifai, Sarah Sabah, Zainalabedeen M Tarakji, Adam M Rifai, Ahmad O Dahan, Sally Denig, Kristin M Cutaneous Leukocytoclastic Vasculitis Induced by Apixaban and/or Rivaroxaban With Seronegative Anti-Neutrophil Cytoplasmic Antibody (ANCA) Titers: A Case Report and Literature Review |
title | Cutaneous Leukocytoclastic Vasculitis Induced by Apixaban and/or Rivaroxaban With Seronegative Anti-Neutrophil Cytoplasmic Antibody (ANCA) Titers: A Case Report and Literature Review |
title_full | Cutaneous Leukocytoclastic Vasculitis Induced by Apixaban and/or Rivaroxaban With Seronegative Anti-Neutrophil Cytoplasmic Antibody (ANCA) Titers: A Case Report and Literature Review |
title_fullStr | Cutaneous Leukocytoclastic Vasculitis Induced by Apixaban and/or Rivaroxaban With Seronegative Anti-Neutrophil Cytoplasmic Antibody (ANCA) Titers: A Case Report and Literature Review |
title_full_unstemmed | Cutaneous Leukocytoclastic Vasculitis Induced by Apixaban and/or Rivaroxaban With Seronegative Anti-Neutrophil Cytoplasmic Antibody (ANCA) Titers: A Case Report and Literature Review |
title_short | Cutaneous Leukocytoclastic Vasculitis Induced by Apixaban and/or Rivaroxaban With Seronegative Anti-Neutrophil Cytoplasmic Antibody (ANCA) Titers: A Case Report and Literature Review |
title_sort | cutaneous leukocytoclastic vasculitis induced by apixaban and/or rivaroxaban with seronegative anti-neutrophil cytoplasmic antibody (anca) titers: a case report and literature review |
topic | Allergy/Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540658/ https://www.ncbi.nlm.nih.gov/pubmed/37779775 http://dx.doi.org/10.7759/cureus.44376 |
work_keys_str_mv | AT elsabbaghmohamad cutaneousleukocytoclasticvasculitisinducedbyapixabanandorrivaroxabanwithseronegativeantineutrophilcytoplasmicantibodyancatitersacasereportandliteraturereview AT rifaisarah cutaneousleukocytoclasticvasculitisinducedbyapixabanandorrivaroxabanwithseronegativeantineutrophilcytoplasmicantibodyancatitersacasereportandliteraturereview AT sabahzainalabedeenm cutaneousleukocytoclasticvasculitisinducedbyapixabanandorrivaroxabanwithseronegativeantineutrophilcytoplasmicantibodyancatitersacasereportandliteraturereview AT tarakjiadamm cutaneousleukocytoclasticvasculitisinducedbyapixabanandorrivaroxabanwithseronegativeantineutrophilcytoplasmicantibodyancatitersacasereportandliteraturereview AT rifaiahmado cutaneousleukocytoclasticvasculitisinducedbyapixabanandorrivaroxabanwithseronegativeantineutrophilcytoplasmicantibodyancatitersacasereportandliteraturereview AT dahansally cutaneousleukocytoclasticvasculitisinducedbyapixabanandorrivaroxabanwithseronegativeantineutrophilcytoplasmicantibodyancatitersacasereportandliteraturereview AT denigkristinm cutaneousleukocytoclasticvasculitisinducedbyapixabanandorrivaroxabanwithseronegativeantineutrophilcytoplasmicantibodyancatitersacasereportandliteraturereview |